Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P) Abstract #99

Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.
Aim(s): To evaluate the expression of gene mutation and HIF-1 levels in P/P. In addition, these alterations as prognostic–predictive factors in P/P have been considered.
Materials and methods: A retrospective analysis of 30 P/P cases treated in our Istitute from 1999 to October 2009 was carried out. Nineteen patients had paragangliomas while the remaining 11 had pheochromocytomas. The main patient characteristics were: median age 49 yrs. (range 21-80); 16 males and 14 females; and the most common sites of disease were bone (36%), lymphnodes (30%), lung (16%), liver (16%). Twenty-six patients underwent resection of the primary tumor, while eight and 12 patients, respectively, were treated with chemotherapy and/or metabolic therapy. Additionally, in 12 patients the immunohistochemical evaluation of the SDHB mutation and the assessment of HIF-1 levels was carried out. The staining for SDHDB was optimized employing micro-slices of normal myocardial atrial muscle as positive control. To ensure antibody specificity, consecutive sections were incubated in absence of a primary antibody. The immunoreactivity was evaluated on a semiquantitative scale considering the extent (score 0-4) and the intensity (score 0-3) of staining. The product was used to obtain an immuno-staining score (total score 0-12).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta

To read results and conclusion, please login ...

Further abstracts you may be interested in

#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling
Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Anja M Schmitt
#480 Immunohistochemical (IHC) Overexpression of Succinate Dehydrogenase (SDHB) as Prognostic Factor in Sporadic Pheochromocytomas/Paragangliomas (P/P)
Introduction: Recently, gene mutations (SDH complex) involved in the pathogenesis of familial P/P have been discovered. These mutations are often associated with SDHB activity loss and activation of hypoxia signals.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
#581 Loss of Succinate Dehydrogenase (SDHB) Expression in Midgut Carcinoids as Prognostic Factor: a New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of SDH complex have been involved in the pathogenesis of cancer cells. These mutations are often associated with loss of activity of SDH subunity B and overexpression of HIF-1a, which play a central role in angiogenesis.
Conference:
Category: Basic
Presenting Author: Dr. Massimo Milione
#645 Loss of Succinate Dehydrogenase (SDHB) in Midgut Carcinoids as Prognostic Factor: A New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of the succinate dehydrogenase (SDH) complex are involved in the pathogenesis of cancer cells and play a pivotal role in angiogenesis and cell proliferation. The immunoistochemical (IHC) loss of SDHB is a marker of malignancy in pheocromocytomas and paragangliomas.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Md, PhD Massimo Milione
Keywords: midgut, SDHB
#473 Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?
Introduction: The immunoistochemical (IHC) loss of SDHB expression was reported as a surrogate marker of malignancy in sporadic and familial pheocromocytomas/paragangliomas. SDHB loss is supposed to be tumorigenic (activation hypoxia signals).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
Keywords: SDHB